Abstract：
UNASSIGNED: The aim of this study was to evaluate local tumor control and complication development rates of fractionated CyberKnife radiosurgery (CRS) in patients with choroidal melanoma.
UNASSIGNED: A total of 29 patients with choroidal melanoma were treated with fractionated CRS at Ankara Oncology Research and Training Hospital, Department of Radiotherapy between May 2009 and December 2013. Patients were treated with CRS if the initial height of the choroidal melanoma was ≥ 6 mm, or juxtapapillary and/or juxtamacular tumors with a height of >2.5 mm. Ophthalmic examinations were performed at baseline and at months 3, 6, 9 and 15 after radiotherapy. Assessment of visual acuity and measurement of tumor base dimension and height using A-scan and B-scan echography were done at each visit.
UNASSIGNED: The mean age was 56 (27-75) years. Tumor was located on choroid in 23 and on ciliochoroid in 6 patients. 86.2% of all melanomas were classified as medium sized and 23.8% as large sized. A median total dose of 5000 cGy was applied. Median tumor height decreased from 7.5 mm at baseline to 4.4 mm at the last follow-up visit (p < 0.001). Median visual acuity decreased from 0.4 at baseline to hand motion (p < 0.001). One patient had been lost to the metastatic disease and one patient had been treated with enucleation due to recurrent tumor growth.
UNASSIGNED: CRS is an effective and reliable local treatment modality in uveal melanoma.
UNASSIGNED: A total of 29 patients with choroidal melanoma were treated with fractionated CRS at Ankara Oncology Research and Training Hospital, Department of Radiotherapy between May 2009 and December 2013. Patients were treated with CRS if the initial height of the choroidal melanoma was ≥ 6 mm, or juxtapapillary and/or juxtamacular tumors with a height of >2.5 mm. Ophthalmic examinations were performed at baseline and at months 3, 6, 9 and 15 after radiotherapy. Assessment of visual acuity and measurement of tumor base dimension and height using A-scan and B-scan echography were done at each visit.
UNASSIGNED: The mean age was 56 (27-75) years. Tumor was located on choroid in 23 and on ciliochoroid in 6 patients. 86.2% of all melanomas were classified as medium sized and 23.8% as large sized. A median total dose of 5000 cGy was applied. Median tumor height decreased from 7.5 mm at baseline to 4.4 mm at the last follow-up visit (p < 0.001). Median visual acuity decreased from 0.4 at baseline to hand motion (p < 0.001). One patient had been lost to the metastatic disease and one patient had been treated with enucleation due to recurrent tumor growth.
UNASSIGNED: CRS is an effective and reliable local treatment modality in uveal melanoma.
摘要：
UNASSIGNED：本研究的目的是评估脉络膜黑色素瘤患者的局部肿瘤控制率和分割射波刀放射外科（CRS）并发症发生率。
UNASSIGNED：共有29名脉络膜黑色素瘤患者在安卡拉肿瘤研究和培训医院接受了部分CRS治疗，2009年5月至2013年12月之间的放射治疗部门。如果脉络膜黑色素瘤的初始高度≥6mm，则患者接受CRS治疗。或高度>2.5mm的并乳头状肿瘤和/或并杂音肿瘤。在基线和放疗后第3、6、9和15个月进行眼科检查。每次就诊时使用A扫描和B扫描回波描记术评估视力并测量肿瘤的基本尺寸和高度。
未经评估：平均年龄为56（27-75）岁。23例肿瘤位于脉络膜，6例位于纤毛脉络膜。所有黑素瘤的86.2％被分类为中型，23.8％被分类为大型。施用的中值总剂量为5000cGy。中位肿瘤高度从基线时的7.5mm下降到最后一次随访时的4.4mm(p<0.001)。中位视敏度从基线时的0.4下降到手部运动(p<0.001)。一名患者因转移性疾病而丧失，一名患者因复发性肿瘤生长而接受了摘除治疗。
UNASSIGNED：CRS是葡萄膜黑色素瘤的一种有效且可靠的局部治疗方式。
UNASSIGNED：共有29名脉络膜黑色素瘤患者在安卡拉肿瘤研究和培训医院接受了部分CRS治疗，2009年5月至2013年12月之间的放射治疗部门。如果脉络膜黑色素瘤的初始高度≥6mm，则患者接受CRS治疗。或高度>2.5mm的并乳头状肿瘤和/或并杂音肿瘤。在基线和放疗后第3、6、9和15个月进行眼科检查。每次就诊时使用A扫描和B扫描回波描记术评估视力并测量肿瘤的基本尺寸和高度。
未经评估：平均年龄为56（27-75）岁。23例肿瘤位于脉络膜，6例位于纤毛脉络膜。所有黑素瘤的86.2％被分类为中型，23.8％被分类为大型。施用的中值总剂量为5000cGy。中位肿瘤高度从基线时的7.5mm下降到最后一次随访时的4.4mm(p<0.001)。中位视敏度从基线时的0.4下降到手部运动(p<0.001)。一名患者因转移性疾病而丧失，一名患者因复发性肿瘤生长而接受了摘除治疗。
UNASSIGNED：CRS是葡萄膜黑色素瘤的一种有效且可靠的局部治疗方式。
